Related references
Note: Only part of the references are listed.Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors
Ophelia Yin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
Natsumi Namba et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
Dwan-Ying Chang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
Sihem Ait-Oudhia et al.
AAPS JOURNAL (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Hirdesh Uppal et al.
CLINICAL CANCER RESEARCH (2015)
Increased Expression of Cathepsin L: A Novel Independent Prognostic Marker of Worse Outcome in Hepatocellular Carcinoma Patients
Jian Ruan et al.
PLOS ONE (2014)
Cathepsin B: Multiple roles in cancer
Neha Aggarwal et al.
PROTEOMICS CLINICAL APPLICATIONS (2014)
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production
Jonathan N. Thon et al.
BLOOD (2012)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Cardiotoxicity profile of trastuzumab
Steven M. Ewer et al.
DRUG SAFETY (2008)
Pulmonary toxicity from novel antineoplastic agents
I Dimopoulou et al.
ANNALS OF ONCOLOGY (2006)
Share Paper
